The Future of Psoriasis Management: Integration, Innovation, and Holistic Care

The landscape of psoriasis management has been transformed over the past two decades, and real-world data from meetings like Winter Clinical Hawaii 2026 reflect just how far the field has come. The availability of a diverse armamentarium—from nonsteroidal topicals to highly targeted biologics—has enabled clinicians to set and pursue more ambitious treatment goals. Today, achieving complete or near-complete skin clearance is not merely aspirational; it is increasingly the standard against which treatment success is measured. Patient-reported outcomes and satisfaction data have reinforced this shift, revealing that patients themselves perceive a meaningful quality-of-life gap between "clear" and "almost clear."

Thinking about psoriasis as psoriatic disease—a systemic condition with skin manifestations that often co-occur with psoriatic arthritis, cardiometabolic risk, and other comorbidities—has also reshaped treatment philosophy. Therapy selection is increasingly guided by the full clinical picture rather than skin disease alone. The emergence of oral IL-23 inhibitors represents the next frontier, offering patients who prefer oral routes of administration a potent new option that may further expand access and adherence.

Looking ahead, opportunities for improvement abound. Genotypic profiling and biomarker research hold promise for identifying which therapies are best suited to individual patients before the first dose is administered—removing some of the uncertainty that still characterizes initial treatment selection. Addressing access disparities and regional inequities in formulary coverage remains a critical priority if the gains made in clinical efficacy are to be realized across all patient populations. And continued attention to holistic outcomes, including cardiovascular and metabolic health, will be essential as the field matures beyond skin clearance toward true long-term wellness for patients with psoriatic disease.

References

1. Chovitaya R, Soung J, Jaworski JC, Seal MS, Hanna D, Stephenson B. Real-world insights into first-line use of topical roflumilast cream for psoriasis. Poster presented at: Winter Clinical Dermatology Conference; January 16-21, 2026; Maui, Hawaii.

2. Lockshin B, Beeghly A, Blachley T, Eliot M, Barghout V, Mathew J, Ferro T, Prajapati VH. Real-world tildrakizumab persistence in the US by biologic experience and insurance coverage in the PPD CorEvitas Psoriasis Registry. Poster presented at: Winter Clinical Dermatology Conference; January 16-21, 2026; Maui, Hawaii.

3. Prajapati VH, Blachley T, Eliot M, et al. Regional differences in patient characteristics among US biologic initiators from the PPD CorEvitas Psoriasis Registry. Poster presented at: Winter Clinical Dermatology Conference; January 16-21, 2026; Maui, Hawaii.